Related Experiment Videos
[Development of resistance to difuracil (PAP-49) in bacteria and its activity in combination with other antibacterial
Abstract:
Possible increasing of resistance to difuracil or N-(5-nitrofurfuryliden)-5-nitrofuran-2-(N'-acetyl) carboxamidohydrazon (PAP-49) in Staphylococcus sp., Streptococcus sp. and Escherichia coli was studied and the level of the resistance increasing was determined by the method of 30-fold passage of the cultures in subbacteriostatic concentrations of the drug. It was shown in vitro that the increase of the resistance to the new nitrofuran was insignificant. The most intensive adaptation was observed during the first 10 passages. During the following 10-15 passages the susceptibility level remained unchanged (E.coli) or was even somewhat higher (S. aureus and Streptococcus sp.). After that a new increase of the resistance was observed. The most marked changes in the susceptibility were detected in Streptococcus sp. and the least marked in Staphylococcus sp. and E.coli. Combinations of difuracil in subbacteriostatic concentrations with various antibacterial drugs provided both additive and synergistic effects with respect to S.epidermidis, S. pneumonase, E.coli and P.mirabilis. The most active combinations were those of difuracil with aminoglycoside antibiotics, penicillins or chloramphenicol.
Insights
This study investigated bacterial resistance to difuracil, a new nitrofuran drug. In vitro results showed insignificant resistance increases in Staphylococcus, Streptococcus, and Escherichia coli, with notable synergistic effects when combined with other antibiotics.
Area of Science:
- Microbiology
- Pharmacology
- Antimicrobial Resistance
Background:
- Emerging bacterial resistance necessitates the development of new antimicrobial agents.
- Nitrofuran derivatives represent a class of compounds with potential antibacterial activity.
- Understanding the resistance mechanisms and potential synergistic effects of new drugs is crucial for effective treatment strategies.
Purpose of the Study:
- To evaluate the in vitro development of resistance to difuracil (a novel nitrofuran) in key bacterial species.
- To determine the susceptibility changes of Staphylococcus sp., Streptococcus sp., and Escherichia coli after repeated exposure to sub-bacteriostatic concentrations of difuracil.
- To investigate the potential additive and synergistic effects of difuracil in combination with other antibacterial drugs.
Main Methods:
- Bacterial cultures (Staphylococcus sp., Streptococcus sp., Escherichia coli) were subjected to 30 passages in sub-bacteriostatic concentrations of difuracil.
- Minimum inhibitory concentrations (MICs) were determined to assess changes in susceptibility.
- In vitro combination studies were performed using difuracil with various classes of antibiotics against selected bacterial strains.
Main Results:
- In vitro studies demonstrated an insignificant increase in resistance to difuracil across the tested bacterial species.
- The most rapid adaptation occurred within the first 10 passages, with susceptibility stabilizing or slightly increasing in subsequent passages.
- Streptococcus sp. exhibited the most pronounced susceptibility changes, while Staphylococcus sp. and E. coli showed the least.
- Combinations of difuracil with aminoglycosides, penicillins, or chloramphenicol exhibited additive or synergistic effects against S. epidermidis, S. pneumoniae, E. coli, and P. mirabilis.
Conclusions:
- Difuracil exhibits a low potential for inducing significant bacterial resistance in vitro.
- The combination of difuracil with established antibiotic classes can enhance antibacterial efficacy, suggesting potential for novel therapeutic strategies.
- Further research into difuracil's clinical applications and resistance profiles is warranted.